Last €90.30 EUR
Change Today +2.30 / 2.61%
Volume 1.0K
BIO On Other Exchanges
Symbol
Exchange
Xetra
Xetra
OTC US
OTC US
OTC US
As of 7:47 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Open
€89.00
Previous Close
€88.00
Day High
€90.33
Day Low
€88.81
52 Week High
07/7/14 - €94.70
52 Week Low
08/12/14 - €68.50
Market Cap
1.2B
Average Volume 10 Days
7.2K
EPS TTM
€2.10
Shares Outstanding
6.6M
EX-Date
05/8/14
P/E TM
43.0x
Dividend
€0.57
Dividend Yield
0.63%
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,137 Employees
Last Reported Date: 11/12/14
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €513.0K
Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €459.0K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €353.0K
Compensation as of Fiscal Year 2013.

biotest ag (BIO) Key Developments

Biotest Encourages Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in Combination with Lenalidomide and Dexamethasone

Biotest presented new clinical data derived from an ongoing combination study with BT-062 at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco. The Phase I/IIa study (Study 983) in multiple myeloma is investigating the safety and efficacy of BT-062 in combination with lenalidomide and dexamethasone in patients who have not been responding (any more) to previous treatments. In the study, a total of 47 patients were treated with three different dosages up to maximum of 120 mg/m- BT-062, used in combination with lenalidomide and dexamethasone. Patients were treated until progression of the underlying disease or occurrence of unacceptable toxicities. 25 of the 47 patients enrolled are currently still on treatment, partly for up to 23 months. Currently available efficacy data were evaluated from those 41 patients who had at least two efficacy assessments since the start of the treatment. All of these heavily pretreated patients showed clinical benefit from the therapy, achieving a stable disease or better. 78% of these patients had an objective response which ranges from a partial response to stringent complete response. Up to now 10% of the patients had a complete remission. Even in patients previously treated with both lenalidomide and bortezomib, an objective response rate of 68% was obtained. The available data indicate that BT-062 is well tolerated in this combination regimen up to doses of 100 mg/m-. Among the patients treated with the maximal tolerated dose (100 mg/m-), even 83% had an objective response. Based on these encouraging data, it is planned to also evaluate safety and efficacy of BT-062 in combination with pomalidomide and dexamethasone in patients already exposed to lenalidomide and bortezomib. Besides the multiple myeloma cells also many solid tumors express high levels of the CD 138 receptor. Biotest is conducting a monotherapy phase I/IIa study (Study 989) in triple negative metastatic breast cancer and metastatic urinary bladder cancer in Belgium and Germany.

Biotest AG Receives Marketing Authorization for Human Albumin Solution in China

Biotest AG announced that it has received the marketing authorization for Albiomin 20%, or solution of human albumin, from the Chinese FDA. Human albumin is used for stabilization of the blood circulation in severe diseases such as burns as well as chronic diseases of the liver and kidneys or complications associated with protein loss. In the Chinese pharmaceutical market only human albumin made from US plasma is authorized for selling. For this company international production structure offers unparalleled advantages. Plasma collected from US blood donors is the source material for Albiomin 20% for the Chinese market. With the distribution partner of the company, Wanbang iopharmaceuticals, Shanghai. The company expects to be on the Chinese market with Albiomin 20% from 2015 onwards. First sales are expected beginning of 2015 after the batch release by the authorities.

Biotest Presents New Preclinical Data on Tregalizumab (BT-061)

Biotest AG announced that data from in vitro studies on tregalizumab. Tregalizumab is an antibody that selectively activates naturally occurring regulatory T cells (Tregs), and is currently in Phase 2b clinical development for the treatment of rheumatoid arthritis (RA). This mode of action is unique and totally different from other treatment modalities currently used in RA. Activating regulatory cells may yield high treatment efficacy with less side effects due to lower over all suppression of the immune system. The presented in vitro studies examined the potential of tregalizumab to activate regulatory T-cells in the presence of high levels of pro-inflammatory cytokines as observed in patients with autoimmune diseases such as RA. Further investigations focused on the influence of methotrexate which is widely used as co-medication in RA in combination with tregalizumab. The experiments show that the in vitro activation of regulatory T-cells by tregalizumab is not inhibited either by MTX or by pro-inflammatory cytokines (IL-1?, IL-6 and TNF-?). The scientific evaluation was done in collaboration with the research group of Dr. Helmut Jonuleit, University of Mainz.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €90.30 EUR +2.30

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies
 

Industry Analysis

BIO

Industry Average

Valuation BIO Industry Range
Price/Earnings 41.8x
Price/Sales 2.1x
Price/Book 2.4x
Price/Cash Flow 20.9x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit www.biotest.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.